Publication:
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

dc.contributor.authorBilici, Ahmet
dc.contributor.authorKoca, Sinan
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorEraslan, Emrah
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorOcak, Birol
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorPaydas, Semra
dc.contributor.authorAkgul, Fahri
dc.contributor.authorDerin, Sumeyye
dc.contributor.authorErgun, Yakup
dc.contributor.authorYekeduz, Emre
dc.contributor.authorErol, Cihan
dc.contributor.authorOzyukseler, Deniz Tataroglu
dc.contributor.authorDemiray, Atike Gokcen
dc.contributor.authorKaraca, Mustafa
dc.contributor.authorGuc, Zeynep Gulsum
dc.contributor.authorMenekse, Serkan
dc.contributor.authorCinkir, Havva Yesil
dc.contributor.authorGumusay, Ozge
dc.contributor.authorSakin, Abdullah
dc.contributor.authorÖzkul, Özlem
dc.contributor.authorDemir, Hacer
dc.contributor.authorErdem, Dilek
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorAcar, Ramazan
dc.contributor.authorKoral, Lokman
dc.contributor.authorSahin, Suleyman
dc.contributor.authorSakalar, Teoman
dc.contributor.authorBahceci, Aykut
dc.contributor.authorÖzveren, Ahmet
dc.contributor.authorGunaydin, Ulug Mutlu
dc.contributor.authorŞeker, Mehmet Metin
dc.contributor.authorSunar, Veli
dc.contributor.authorDal, Pinar
dc.contributor.authorArtac, Mehmet
dc.contributor.authorTurhal, Serdar
dc.contributor.buuauthorOCAK, BİROL
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Onkoloji Ana Bilim Dalı
dc.contributor.researcheridAEC-2238-2022
dc.date.accessioned2024-12-03T07:15:37Z
dc.date.available2024-12-03T07:15:37Z
dc.date.issued2023-04-17
dc.description.abstractAimDescription of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS).Patients and methodsThis multicenter study is based on retrospective review of hospital medical records of patients (>= 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort.ResultsData of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG >= 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as >= 3 in 8.2% and 7.4% of patients, respectively.ConclusionPazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.
dc.identifier.doi10.1007/s00432-023-04766-3
dc.identifier.endpage8253
dc.identifier.issn0171-5216
dc.identifier.issue11
dc.identifier.startpage8243
dc.identifier.urihttps://doi.org/10.1007/s00432-023-04766-3
dc.identifier.urihttps://link.springer.com/article/10.1007/s00432-023-04766-3
dc.identifier.urihttps://hdl.handle.net/11452/48815
dc.identifier.volume149
dc.identifier.wos000972021200003
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherSpringer
dc.relation.journalJournal of Cancer Research and Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMultikinase angiogenesis inhibitor
dc.subjectEuropean organization
dc.subjectClinical-trials
dc.subjectEortc
dc.subjectPazopanib
dc.subjectSoft tissue sarcoma
dc.subjectTargeted therapy
dc.subjectSynovial sarcoma
dc.subjectLeiomyosarcoma
dc.subjectMetastatic soft tissue sarcoma
dc.subjectOncology
dc.titleReal-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication2f0a7090-a0f8-4520-aa3f-0171466752bd
relation.isAuthorOfPublication.latestForDiscovery2f0a7090-a0f8-4520-aa3f-0171466752bd

Files